Skip to main content
EJNMMI Research
Fig. 7 | EJNMMI Research

Fig. 7

From: Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine

Fig. 7

NGAL (ng/mL ± SEM) level in control and 213Bi-DOTATATE-treated cohorts with (+) or without (−) pre-treatment of l-lysine (35 mg). Cohort low-dose(−) received cumulatively 13.0 ± 1.6 MBq, low-dose(+) 13.2 ± 0.9 MBq, medium-dose(−) 20.7 ± 0.8 MBq, medium-dose(+) 21.7 ± 1.9 MBq, high-dose(−) 28.7 ± 1.2 MBq, and high-dose(+) 28.3 ± 0.8 MBq. Control animals received 4 × 0.3 nmol DOTATATE. **P value <0.01 and *** P value <0.001 versus control values

Back to article page